Status:
UNKNOWN
Circulating and Imaging Biomarkers to Improve Lung Cancer Management and Early Detection
Lead Sponsor:
Istituto Clinico Humanitas
Collaborating Sponsors:
Ospedale San Raffaele
University of Paris 5 - Rene Descartes
Conditions:
Lung Cancer
Eligibility:
All Genders
55+ years
Brief Summary
Validation of biomolecular markers in the circulation and radiomic features are the focus of this project.The aim is to assess the role of molecular and cellular biomarkers (exosomes antigens, Circula...
Eligibility Criteria
Inclusion
- Age ≥ 55 years old and exposure to smoking more than 30 packs-year; which corresponds to 6-year risk of lung cancer, calculated according to the plco score (≥ 2%).
- Smoker or former smoker Former smokers must have ceased smoking within the 15 years prior to enrollment in the study.
- Absence of symptoms of lung cancer such as worsening of cough, hoarseness, hemoptysis and weight loss.
Exclusion
- Previous diagnosis of lung cancer.
- Positive extrapulmonary cancer history in the last 5 years (excluding in situ tumors or skin epidermoid tumor).
- Performing a chest CT scan in the last 18 months.
- Severe lung or extrapulmonary diseases that may preclude or invalidate appropriate therapy in case of diagnosis of malignant pulmonary neoplasia.
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2023
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT04315753
Start Date
January 1 2018
End Date
January 1 2023
Last Update
March 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Clinico Humanitas
Rozzano, Milano, Italy, 20089